<DOC>
	<DOCNO>NCT00286793</DOCNO>
	<brief_summary>This open-label , multicenter Phase I/II study evaluate safety efficacy AT-101 combination docetaxel prednisone men hormone-refractory prostate cancer either chemotherapy naive receive progressed docetaxel contain regimen ,</brief_summary>
	<brief_title>Safety Efficacy Study AT-101 Combination With Docetaxel Prednisone Men With HRPC</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gossypol acetic acid</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Gossypol</mesh_term>
	<criteria>1 . Rising prostate specific antigen ( PSA ) despite castrate level testosterone due orchiectomy luteinizing hormonereleasing hormone ( LHRH ) agonist therapy . 2 . Patients must metastatic disease bone scan , compute tomography ( CT ) scan , magnetic resonance imaging ( MRI ) . 3 . ECOG performance status 0 1 4 . Adequate hematologic function 5 . Adequate liver renal function 6 . Able swallow retain oral medication . 7 . Patients enrol Cohort B must document progression disease treatment docetaxelcontaining regimen meet one follow criterion rise PSA , progression disease per RECIST , &gt; 2 new lesion bone scan . 8 . Patients enrol Cohort B must receive least two cycle docetaxel . Minimum dos prior docetaxel permit 60 mg/m2 q 3 week schedule 20 mg/m2 weekly schedule . 9 . At least 4 week since prior flutamide , megestrol , ketoconazole , radiotherapy , least 6 week since prior bicalutamide nilutamide . 1 . Patients enrol Cohort A must receive prior chemotherapy HRPC . 2 . Known history clinical evidence central nervous system ( CNS ) metastases . 3 . Active secondary malignancy history malignancy within last 5 year . 4 . Prior history radiation therapy &gt; 25 % bone marrow 5 . Peripheral neuropathy &gt; Grade 2 6 . Uncontrolled concurrent illness 7 . Failure recover fully , judge investigator , prior surgical procedure . 8 . Concurrent anticancer therapy docetaxel prednisone . 9 . Patients must receive concurrent antiandrogen hormonal therapy HRPC ( LHRH therapies acceptable maintain castrate level testosterone )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>at-101</keyword>
	<keyword>at101</keyword>
	<keyword>cancer</keyword>
	<keyword>hormone refractory</keyword>
	<keyword>prostate</keyword>
	<keyword>docetaxel</keyword>
	<keyword>prednisone</keyword>
</DOC>